Tag: Regeneron

All

FDA: Two Monoclonal Antibody Treatments Ineffective Against Omicron Variant

The FDA has removed two monoclonal antibody therapies from its list of emergency authorized COVID-19 treatments due to their ineffectiveness against the Omicron variant.

Regen-Cov Reduced COVID Risk for up to Eight Months
Dupilumab Gets Expanded Approval for Moderate-to-severe Asthma in Children Age 6-11
Dupilumab May Improve Lung Function in Children Age 6-11 with Uncontrolled, Moderate to Severe Asthma
WHO Recommends Regen-COV for COVID-19 Patients at High Risk of Hospital Admission
FDA Expands Authorized Use of Regen-Cov as Preventative Treatment
Libtayo plus Chemo Significantly Improved Overall Survival in Advanced NSC Lung Cancer
Regen-Cov Reduced COVID-19 Hospital Mortality by 20% in Seronegative Patients

All

FDA Okays Lower Dose of Regeneron Monoclonal Antibody Cocktail

Regeneron's COVID-19 monoclonal antibody cocktail (casirivimab + imdevimab) is now authorized at half the dose for patients age 12 and older.

Regeneron Monoclonal Antibodies Reduced COVID-19 Transmission Risk by 81%
FDA Authorizes Regeneron’s Monoclonal Antibody Treatment for COVID-19

Tag: Regeneron

All

FDA: Two Monoclonal Antibody Treatments Ineffective Against Omicron Variant

Regen-Cov Reduced COVID Risk for up to Eight Months

Dupilumab Gets Expanded Approval for Moderate-to-severe Asthma in Children Age 6-11

Dupilumab May Improve Lung Function in Children Age 6-11 with Uncontrolled, Moderate to Severe Asthma

WHO Recommends Regen-COV for COVID-19 Patients at High Risk of Hospital Admission

FDA Expands Authorized Use of Regen-Cov as Preventative Treatment

Libtayo plus Chemo Significantly Improved Overall Survival in Advanced NSC Lung Cancer

Regen-Cov Reduced COVID-19 Hospital Mortality by 20% in Seronegative Patients

All

FDA Okays Lower Dose of Regeneron Monoclonal Antibody Cocktail

Regeneron Monoclonal Antibodies Reduced COVID-19 Transmission Risk by 81%

FDA Authorizes Regeneron’s Monoclonal Antibody Treatment for COVID-19

All

Sorry, No Posts Found

Sorry, No Posts Found